Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis Ag ADR
(NY:
NVS
)
118.56
+0.80 (+0.68%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Uncovering Dividend Opportunities with NYSE:NVS.
August 23, 2024
Balancing Dividends and Fundamentals: The Case of NOVARTIS AG-SPONSORED ADR (NYSE:NVS).
Via
Chartmill
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
August 18, 2024
These companies' growth paths should only be briefly interrupted by headwinds.
Via
The Motley Fool
Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
August 13, 2024
Novartis faces a legal setback as a federal court allows MSN Pharmaceuticals to launch a generic version of Entresto, its top-selling heart-failure drug. The decision pressures Novartis to explore...
Via
Benzinga
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
August 08, 2024
Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression....
Via
Benzinga
Exposures
Product Safety
Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR.
August 07, 2024
The question on everyone's mind: Will NOVARTIS AG-SPONSORED ADR breakout?
Via
Chartmill
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
August 06, 2024
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Why NYSE:NVS is a Top Pick for Dividend Investors.
August 02, 2024
Why the dividend investor may take a look at NOVARTIS AG-SPONSORED ADR (NYSE:NVS).
Via
Chartmill
Novartis Reports Near 40% Margin In Q2; Shares Slide
July 18, 2024
Novartis topped Q2 views and lifted guidance. Shares eased after a four-month run.
Via
Investor's Business Daily
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
July 23, 2024
The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market.
Via
Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
The Nasdaq tumbled amid chip woes.
Via
Investor's Business Daily
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
July 18, 2024
NVS earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
July 18, 2024
Investors were caught off guard by a decision on the research and development front.
Via
The Motley Fool
Is NYSE:NVS a Good Fit for Dividend Investing?
July 12, 2024
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing?
Via
Chartmill
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
July 18, 2024
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs
July 18, 2024
Novartis reports strong Q2 results with adjusted EPS of $1.97, up 21% YoY, and sales at $12.51 billion, up 11%. Key drivers include Entresto, Kesimpta, Cosentyx, Kisqali, Leqvio, and Pluvicto. The...
Via
Benzinga
Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens
July 18, 2024
Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong quarterly repo
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Alnylam Stock Is a Blockbuster Biopharma In the Making
July 18, 2024
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market.
Via
InvestorPlace
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q2 2024
July 18, 2024
NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
2 Magnificent Stocks to Buy With $500
July 18, 2024
These reliable healthcare companies look attractive no matter how you slice it.
Via
The Motley Fool
D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday
July 18, 2024
Via
Benzinga
3 Global Stocks to Buy to Escape the Volatility on Wall Street
July 16, 2024
Discover three top global stocks as a smart hedge against Wall Street volatility, offering diversification and resilience in uncertain times.
Via
InvestorPlace
3 Spinoff Stocks You Should Buy Now: July 2024
July 15, 2024
Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early.
Via
InvestorPlace
Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years
July 15, 2024
Following a lackluster big bank earnings, market participants now turn their attention to the unfolding week, expecting the trend to reverse.
Via
Benzinga
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
July 13, 2024
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector.
Via
InvestorPlace
3 Healthcare Stocks Injecting AI for Big Gains
July 13, 2024
Investors should keep a close eye on these AI healthcare stocks as they revolutionize the future of drug development and patient care.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
July 12, 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Novartis Stock Generating Improved Relative Strength
July 08, 2024
Top and bottom line growth moved higher in Novartis' most recent quarter. EPS rose 17% to $1.80. Revenue increased 10% to $12.1 billion.
Via
Investor's Business Daily
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
July 05, 2024
UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches in financial categorization and highlights similar issues with Novartis...
Via
Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Via
Investor's Business Daily
Upcoming Stock Spinoffs: Should You Pounce or Pass?
July 04, 2024
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.